We propose that a better understanding of the activation-dependent, adenosine-related functional conversion of γδ T cells could lead to γδ T cell-targeted immunotherapies in autoimmunity and other conditions affected by Foxp3+ regulatory T cells. This evidence concerns the gene FOXP3 and Autoimmunity.